Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28450407 | 0.84 | ALDH1A1 (0.31) | ALDH1A1LMNAMAPK1HTT | |
| SCHEMBL4928589 | 0.75 | — | — | |
| SCHEMBL4927320 | 0.75 | ACHE (0.31) | ALDH1A1TSHR | |
| SCHEMBL3317507 | 0.68 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPK1TSHR | |
| SCHEMBL3838037 | 0.68 | ALDH1A1 (0.45) | ALDH1A1MAPK1TSHR | |
| SCHEMBL908704 | 0.67 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPK1HTTTSHR | |
| SCHEMBL11458412 | 0.67 | TSHR (0.45) | ALDH1A1LMNAMAPK1TSHR | |
| SCHEMBL12341859 | 0.64 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPK1HTTTSHR | |
| SCHEMBL447325 | 0.64 | — | — | |
| SCHEMBL28890635 | 0.62 | ALDH1A1 (0.33) | ALDH1A1LMNAMAPK1HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227796-A1 | 7-Amino-6-Hetaryl-1,2,4-Triazolo[1,5-A]Pyrimidine Compounds and the Use Thereof for Controlling Pathogenic Fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20080132412-A1 | 7-Amino-6-Heteroaryl-1,2,4-Triazolo[1,5-A]Pyrimidines and Their Use for Controlling Harmful Fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118844-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING HARMFUL FUNGI AND COMPOSITIONS COMPRISING THEM | BASF SE (DE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1828190-A1 | 7-AMINO-6-HETEROARYL-1,2,4-TRIAZOLOÝ1,5-A¨PYRIMIDINES AND TO THE USE THEREOF FOR COMBATING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1828191-A2 | 7-AMINO-6-HETARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THE USE THEREOF FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066818-A2 | 7-AMINO-6-HETARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THE USE THEREOF FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066799-A1 | 7-AMINO-6-HETEROARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINES AND TO THE USE THEREOF FOR COMBATING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132412-A1 | 7-Amino-6-Heteroaryl-1,2,4-Triazolo[1,5-A]Pyrimidines and Their Use for Controlling Harmful Fungi | HINT1, PRF1, ERG28 | ALDH1A1 1649/4885LMNA 2966/4885MAPK1 1951/4885 |
| US-20080227796-A1 | 7-Amino-6-Hetaryl-1,2,4-Triazolo[1,5-A]Pyrimidine Compounds and the Use Thereof for Controlling Pathogenic Fungi | CYP8B1, CBR3, HDHD5 | ALDH1A1 2419/4885LMNA 961/4885MAPK1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.